Related Experiment Videos
Cyclooxygenase-2 expression in human esophageal carcinoma
K C Zimmermann1, M Sarbia, A A Weber
1Institut für Pharmakologie, Heinrich-Heine-Universität, Düsseldorf, Germany.
Cancer Research
|January 19, 1999
Summary
Cyclooxygenase-2 (COX-2) is highly expressed in most esophageal cancers. Inhibiting COX-2 may be a promising therapeutic strategy for esophageal cancer, as it impacts tumor cell proliferation and apoptosis.
Area of Science:
- Gastroenterology
- Oncology
- Molecular Biology
Background:
- Epidemiological studies suggest nonsteroidal anti-inflammatory drugs reduce esophageal carcinoma risk.
- Cyclooxygenase-2 (COX-2) is implicated in various cancers, but its role in esophageal cancer requires further investigation.
Purpose of the Study:
- To investigate the expression of COX-2 in esophageal squamous cell carcinomas (SCCs) and adenocarcinomas (ADCs).
- To evaluate the functional relevance of COX-2-derived prostaglandins (PGs) in esophageal cancer cell lines.
- To assess the therapeutic potential of COX-2 inhibition in esophageal cancer.
Main Methods:
- Immunohistochemistry to detect COX-2 expression in 172 SCCs and 27 ADCs.
- Western blot analysis to compare COX-1 and COX-2 protein levels in tumor tissues and normal epithelium.
- In vitro studies using esophageal cancer cell lines (OSC-1 and OSC-2) treated with selective COX-2 inhibitors.
Main Results:
- COX-2 was expressed in 91% of SCCs and 78% of ADCs.
- Enhanced COX-2 protein expression was observed in some tumors compared to normal tissue.
- Selective COX-2 inhibition in OSC-2 cells (high COX-2 expressors) suppressed PGE2 synthesis, proliferation, and induced apoptosis, while OSC-1 cells (low COX-2 expressors) showed no response.
Conclusions:
- COX-2 is widely expressed in esophageal SCCs and ADCs.
- COX-2-derived PGs play a significant role in regulating esophageal tumor cell proliferation and apoptosis.
- Targeting COX-2 may represent a viable therapeutic approach for esophageal cancer treatment.